Bibliografía
Fernandez-Banares F, Casanova MJ, Arguedas Y, et al. Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish Microscopic Colitis Group. Aliment Pharmacol Ther 2016;43:400-26.
2. Hjortswang H, Tysk C, Bohr J, et al. Defining clinical criteria for clinical remission and disease activity in collagenous colitis. Inflamm Bowel Dis 2009;15:1875-81.
3. Cotter TG, Binder M, Loftus EV, Jr., et al. Development of a Microscopic Colitis Disease Activity Index: a prospective cohort study. Gut 2018;67:441-446.
4. Miehlke S, Acosta MB, Bouma G, et al. Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinician. J Gastroenterol Hepatol 2018.
5. Johansson SA, Andersson KE, Brattsand R, et al. Topical and systemic glucocorticoid potencies of budesonide, beclomethasone dipropionate and prednisolone in man. Eur J Respir Dis Suppl 1982;122:74-82.
6. Edsbacker S, Andersson P, Lindberg C, et al. Liver metabolism of budesonide in rat, mouse, and man. Comparative aspects. Drug Metab Dispos. 1987 May-Jun;15(3):403-11.
7. Fedorak RN, Bistritz L. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv Drug Deliv Rev 2005;57:303-16.
8. Edsbacker S, Larsson P, Bergstrand M. Pharmacokinetics of budesonide controlled-release capsules when taken with omeprazole. Aliment Pharmacol Ther 2003;17:403-8.
9. Baert F, Schmit A, D'Haens G, et al. Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up. Gastroenterology 2002;122:20-5.
10. Bonderup OK, Hansen JB, Birket-Smith L, et al. Budesonide treatment of collagenous colitis: a randomised, double blind, placebo controlled trial with morphometric analysis. Gut 2003;52:248-51.
11. Miehlke S, Heymer P, Bethke B, et al. Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology 2002;123:978-84.
12. Miehlke S, Madisch A, Kupcinskas L, et al. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis. Gastroenterology 2014;146:1222-30.e1-2.
13. Kafil TS, Nguyen TM, Patton PH, et al. Interventions for treating collagenous colitis. Cochrane Database Syst Rev 2017;11:Cd003575.
14. Sebastian S, Wilhelm A, Jessica L, et al. Budesonide treatment for microscopic colitis: systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2019;31:919-927.
15. Miehlke S, Madisch A, Karimi D, et al. Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study. Gastroenterology 2009;136:2092-100.
16. Pardi DS, Loftus EV, Tremaine WJ, et al. T1193 A Randomized, Double-Blind, Placebo-Controlled Trial of Budesonide for the Treatment of Active Lymphocytic Colitis. Gastroenterology 2009;136:A-519-A-520.
17. Chande N, Al Yatama N, Bhanji T, et al. Interventions for treating lymphocytic colitis. Cochrane Database Syst Rev 2017;7:Cd006096.
Miehlke S, Aust D, Mihaly E, Armerding P, Böhm G, Bonderup O, Fernández-Bañares F, Kupcinskas J, Munck LK, Rehbehn KU, Nacak T, Greinwald R, Münch A; BUG-1/LMC Study Group.Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis. Gastroenterology. 2018 Dec;155(6):1795-1804.e3. doi: 10.1053/j.gastro.2018.08.042.
19. Bonderup OK, Hansen JB, Teglbjaerg PS, et al. Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial. Gut 2009;58:68-72.
20. Miehlke S, Madisch A, Voss C, et al. Long-term follow-up of collagenous colitis after induction of clinical remission with budesonide. Aliment Pharmacol Ther 2005;22:1115-9.
21. Miehlke S, Madisch A, Bethke B, et al. Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2008;135:1510-6.
22. Munch A, Bohr J, Miehlke S, et al. Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial. Gut 2016;65:47-56.
23. Fernandez-Banares F, Piqueras M, Guagnozzi D, et al. Collagenous colitis: Requirement for high-dose budesonide as maintenance treatment. Dig Liver Dis 2017;49:973-977.
24. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994;331:836-41.
25. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. Calcif Tissue Int 2008;82:249-57.
26. Cino M, Greenberg GR. Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy. Am J Gastroenterol 2002;97:915-21.
27. D'Haens G, Verstraete A, Cheyns K, et al. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease. Aliment Pharmacol Ther 1998;12:419-24.
28. Munch A, Aust D, Bohr J, et al. Microscopic colitis: Current status, present and future challenges: statements of the European Microscopic Colitis Group. J Crohns Colitis 2012;6:932-45.
29. Bohr J, Tysk C, Eriksson S, et al. Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients. Gut 1996;39:846-51.
30. Olesen M, Eriksson S, Bohr J, et al. Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients. Gut 2004;53:536-41.
31. Gentile NM, Abdalla AA, Khanna S, et al. Outcomes of patients with microscopic colitis treated with corticosteroids: a population-based study. Am J Gastroenterol 2013;108:256-9.
32. Munck LK, Kjeldsen J, Philipsen E, et al. Incomplete remission with short-term prednisolone treatment in collagenous colitis: a randomized study. Scand J Gastroenterol 2003;38:606-10.
33. Ung KA, Gillberg R, Kilander A, et al. Role of bile acids and bile acid binding agents in patients with collagenous colitis. Gut 2000;46:170-5.
34. Bajor A, Kilander A, Galman C, et al. Budesonide treatment is associated with increased bile acid absorption in collagenous colitis. Aliment Pharmacol Ther 2006;24:1643-9.
35. Pardi DS, Loftus EV, Jr., Tremaine WJ, et al. Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine. Gastroenterology 2001;120:1483-4.
36. Munch A, Fernandez-Banares F, Munck LK. Azathioprine and mercaptopurine in the management of patients with chronic, active microscopic colitis. Aliment Pharmacol Ther 2013;37:795-8.
37. Cotter TG, Kamboj AK, Hicks SB, et al. Immune modulator therapy for microscopic colitis in a case series of 73 patients. Aliment Pharmacol Ther 2017;46:169-174.
38. Riddell J, Hillman L, Chiragakis L, et al. Collagenous colitis: oral low-dose methotrexate for patients with difficult symptoms: long-term outcomes. J Gastroenterol Hepatol 2007;22:1589-93.
39. Munch A, Bohr J, Vigren L, et al. Lack of effect of methotrexate in budesonide-refractory collagenous colitis. Clin Exp Gastroenterol 2013;6:149-52.
40. Esteve M, Mahadevan U, Sainz E, et al. Efficacy of anti-TNF therapies in refractory severe microscopic colitis. J Crohns Colitis 2011;5:612-8.
41. Munch A, Ignatova S, Strom M. Adalimumab in budesonide and methotrexate refractory collagenous colitis. Scand J Gastroenterol 2012;47:59-63.
42. Pola S, Fahmy M, Evans E, et al. Successful use of infliximab in the treatment of corticosteroid dependent collagenous colitis. Am J Gastroenterol 2013;108:857-8.
43. Anderson RJ, Makins R. Successful use of adalimumab in patient with treatment-refractory microscopic colitis. BMJ Case Rep 2016;2016.
44. Cushing KC, Mino-Kenudson M, Garber J, et al. Vedolizumab as a Novel Treatment for Refractory Collagenous Colitis: A Case Report. Am J Gastroenterol 2018;113:632-633.
45. Casper M, Zimmer V, Hubschen U, et al. Vedolizumab for refractory collagenous colitis: Another piece of the puzzle. Dig Liver Dis 2018;50:1099-1100.
46. Jennings JJ, Charabaty A. Vedolizumab-Induced Remission in 3 Patients With Refractory Microscopic Colitis: A Tertiary Care Center Case Series. Inflamm Bowel Dis 2019;25:e97.
47. Riviere P, Munch A, Michetti P, et al. Vedolizumab in Refractory Microscopic Colitis: An International Case Series. J Crohns Colitis 2019;13:337-340.
48. Jarnerot G, Tysk C, Bohr J, et al. Collagenous colitis and fecal stream diversion. Gastroenterology 1995;109:449-55.
49. Munch A, Soderholm JD, Wallon C, et al. Dynamics of mucosal permeability and inflammation in collagenous colitis before, during, and after loop ileostomy. Gut 2005;54:1126-8.